Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline

The lawsuit alleges undisclosed weaknesses in third‑party manufacturing controls that put briquilimab trial readouts at risk of being confounded.

Overview

A federal securities class action has been filed against Jasper Therapeutics covering purchases from November 30, 2023 through July 3, 2025.
Rosen Law Firm and Faruqi & Faruqi are soliciting investors and potential whistleblowers as the November 18, 2025 deadline to move for lead plaintiff approaches.
The complaint asserts Jasper lacked adequate cGMP oversight of third‑party manufacturers, resulting in overstated clinical and commercial prospects for briquilimab.
On July 7, 2025, Jasper said certain BEACON cohorts appeared confounded by a single drug‑product lot also used in ETESIAN, announced halts or pauses in multiple programs including SCID and asthma, and outlined cost‑cutting steps including a potential restructuring.
The disclosure drove a 55.1% drop in Jasper’s share price to $3.04 on July 7, 2025, and the case remains in early stages with no class yet certified.